Financials data is unavailable for this security.
View more
Year on year Shanghai Rightongene Biotechnology Co Ltd 's revenues fell -39.14% from 424.30m to 258.21m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 40.47m to 7.93m, a -80.41% decrease.
| Gross margin | 72.98% |
|---|---|
| Net profit margin | -5.75% |
| Operating margin | -8.78% |
| Return on assets | -1.37% |
|---|---|
| Return on equity | -0.55% |
| Return on investment | -1.46% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Shanghai Rightongene Biotechnology Co Ltd fell by 45.29m. However, the company earned 45.10m from its operations for a Cash Flow Margin of 17.46%. In addition the company generated 11.36m cash from financing while 102.58m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 16.87 |
|---|---|
| Tangible book value per share | 15.64 |
More ▼
Balance sheet in CNYView more
| Current ratio | 12.42 |
|---|---|
| Quick ratio | 11.12 |
| Total debt/total equity | 0.0261 |
|---|---|
| Total debt/total capital | 0.025 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -80.78%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
| EPS growth(5 years) | -16.73 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -121.58 |
